Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

about

Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

P2860

Q40117785-CB89F5B3-3A02-4347-B661-128974163F27 Q57482179-BE54DB2A-63CB-498A-BAB3-E77427C5B5CF

P2860

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Item

http://www.wikidata.org/entity/Q39122007

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Shift from intravenous or 16% ...... primary antibody deficiencies.

@en

Shift from intravenous or 16% ...... primary antibody deficiencies.

@nl

type

Item

label

Shift from intravenous or 16% ...... primary antibody deficiencies.

@en

Shift from intravenous or 16% ...... primary antibody deficiencies.

@nl

prefLabel

Shift from intravenous or 16% ...... primary antibody deficiencies.

@en

Shift from intravenous or 16% ...... primary antibody deficiencies.

@nl

P1476

Shift from intravenous or 16% ...... primary antibody deficiencies

@en

P2093

Alessandra Vultaggio

http://www.w3.org/2001/XMLSchema#string

Alessandro Plebani

http://www.w3.org/2001/XMLSchema#string

Alessia Gatta

http://www.w3.org/2001/XMLSchema#string

Andrea Finocchi

http://www.w3.org/2001/XMLSchema#string

Andrea Matucci

http://www.w3.org/2001/XMLSchema#string

Angelo Vacca

http://www.w3.org/2001/XMLSchema#string

Antonino Trizzino

http://www.w3.org/2001/XMLSchema#string

Antonio Pecoraro

http://www.w3.org/2001/XMLSchema#string

Baldassarre Martire

http://www.w3.org/2001/XMLSchema#string

Carolina Marasco

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

Immunoglobulin therapy: history, indications, and routes of administration.

Subcutaneous immunoglobulin replacement in primary immunodeficiencies.

Subcutaneous administration of immunoglobulin.

Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

Antibody deficiency diseases.

Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.

Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

P304

73-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0394632016681577

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27927705

http://www.w3.org/2001/XMLSchema#string

P932

5806788

http://www.w3.org/2001/XMLSchema#string

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

about

P2860

P2860

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932